Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study.
BACKGROUND
The adipocyte influences eating behavior and metabolism via cytokine secretion. We report our findings of adipokine secretion in a cohort of diabetic and nondiabetic morbidly obese patients before and after Roux-en-Y gastric bypass (RYGB).


METHODS
Ten morbidly obese subjects who underwent uncomplicated RYGB were studied: five were diabetic and nine were female. Nonfasting plasma levels of adiponectin, resistin, leptin, and tumor necrosis factor-alpha were determined preoperatively and 6 mo postoperatively. C-reactive protein (CRP) was followed as a marker of the metabolic syndrome.


RESULTS
The patient age was 42 +/- 11 y, and the preoperative BMI was 50 +/- 6 kg/m(2). The 6 mo BMI fell to 33 +/- 5 kg/m(2) (P < 0.0001), and there were no differences between diabetics and nondiabetics with respect to amount of weight loss. In nondiabetic patients, there were significant increases compared with preoperative levels for adiponectin, resistin, and tumor necrosis factor-alpha; leptin was significantly decreased while CRP was unchanged. CRP and leptin levels were both significantly lower (P < 0.05), while all other protein levels were unchanged in diabetic patients.


CONCLUSIONS
At 6 mo postoperation, RYGB significantly altered most adipokine levels for nondiabetic patients. Only CRP and leptin were changed in diabetic patients. All patients lost a significant amount of weight over 6 mo, suggesting a different metabolic effect between nondiabetic and diabetic patients after RYGB.
Whitson
Bryan A
BA
University of Minnesota Department of Surgery, Division of Gastrointestinal Surgery, Minneapolis, Minnesota 55455, USA.
Leslie
Daniel B
DB
Kellogg
Todd A
TA
Maddaus
Michael A
MA
Buchwald
Henry
H
Billington
Charles J
CJ
Ikramuddin
Sayeed
S
D052242:Adiponectin / Q000097:blood; D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D005260:Female; D015390:Gastric Bypass; D006728:Hormones / Q000097:blood*; D006801:Humans; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism; D008875:Middle Aged; D009767:Obesity, Morbid / Q000378:metabolism* / Q000601:surgery*; D010865:Pilot Projects; D052243:Resistin / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D015431:Weight Loss
D052242:Adiponectin; D015415:Biomarkers; D006728:Hormones; D020738:Leptin; C499624:RETN protein, human; D052243:Resistin; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein